Peter A. Lio, MD
Clinical Assistant Professor of Dermatology and Pediatrics
Northwestern University Feinberg School of Medicine
Chicago Integrative Eczema Center
Mark Boguniewicz, MD
Professor, Division of Allergy-Immunology
Department of Pediatrics
National Jewish Health
and University of Colorado School of Medicine
This enduring virtual activity targets healthcare gaps related to the diagnosis, treatment, and individualized management of AD, impacting outcomes through identifying burdens affecting quality of life, assessing disease severity when considering topical vs systemic intervention, and utilizing strategies in shared decision-making when determining guideline-based care.
- By addressing these gaps, you can assess whether your approach to AD management through utilization of current treatment guidelines, individualization of care through the “step-up care” approach and strategies for disease severity assessment – can be modified to help close these gaps.
- Expert discussion will guide you in analyzing and identifying challenges to AD management, the relationship with Type 2 allergic co-morbid diseases, and how to navigate proactive vs reactive control.
- You will also be immersed in interactive, animated simulation case studies to memorably highlight key points related to assessment of, and treatment decisions for AD.
This activity is intended for allergists, immunologists and other healthcare professionals involved in the management of adult and pediatric patients with moderate-to-severe atopic dermatitis.
Upon the completion of this program, attendees should be able to:
- Assess the disease severity of atopic dermatitis (AD) and its impact on quality of life using clinical presentation, assessment tools, and patient-reported outcomes
- Utilize shared decision-making to design personalized treatment plans for pediatric and adult patients with atopic dermatitis
- Evaluate clinical trial data on the efficacy and safety of systemic treatments that target the underlying chronic inflammation of moderate-to-severe atopic dermatitis
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
This CME activity was planned and produced in accordance with the ACCME Essentials.
CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
NURSING CREDIT INFORMATION
Purpose: This program would be beneficial for nurses involved in the care of patients with atopic dermatitis.
CNE Credits: 1.0 ANCC Contact Hour.
CNE ACCREDITATION STATEMENT
Ultimate Medical Academy/CCM is accredited as a provider of nursing continuing professional education development by the American Nurses Credentialing Center’s Commission on Accreditation.
Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF CONFLICTS OF INTEREST
|Peter Lio, MD||Discloses that he has received research grants/funding from the National Eczema Association, AOBiome, Regeneron/Sanofi Genzyme, and AbbVie. He is on the speaker’s bureau for Regeneron/Sanofi Genzyme, Pfizer, Eli Lilly, LEO Pharma, Galderma, and L’Oréal. He reports consulting/advisory boards for UCB, Dermavant, Regeneron/Sanofi Genzyme, Pfizer, LEO Pharmaceuticals, AbbVie, Eli Lilly, Micreos (stock options), L’Oréal, Pierre-Fabre, Johnson & Johnson, Level Ex, Unilever, Menlo Therapeutics, Theraplex, IntraDerm, Exeltis, AOBiome Therapeutics, Realm Therapeutics, Altus Labs (stock options), Galderma, Verrica Pharmaceuticals, Arbonne, Amyris, Bodewell Skincare, YobeeCare (stock options), Burt’s Bees, My-Or Diagnostics, and Kimberly-Clark. Dr. Lio has a patent pending for a Theraplex product with royalties paid, is an investor in LearnSkin, and is a board member and Scientific Advisory Committee member of the National Eczema Association.|
|Mark Boguniewicz, MD||Discloses that he has served as a consultant for Regeneron, Sanofi Genzyme, AbbVie, Arena, Janssen, Leo Pharma, Lilly and Pfizer. He has also completed contracted research for Regeneron, and Incyte.|
CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.
CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer.
Douglas Cox, MSN, MHA, RN
Ultimate Medical Academy/CCM – Lead Nurse Planner
The reviewer of this activity has nothing to disclose.
Staff Planners and Managers
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
- Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
- Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
- Nicole Longo, DO, FACOI, Director of Medical and Scientific Services for Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
- Lisa Crenshaw, Senior Program Manager for Med Learning Group, has nothing to disclose.
- Morgan Kravarik, Associate Program Manager for Med Learning Group, has nothing to disclose.
- Russie Allen, Accreditation and Outcomes Coordinator for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CME credit for this enduring activity. To receive CME/CNE credit participants must:
- Read the CME/CNE information and faculty disclosures.
- Participate in the enduring activity.
- Complete pre-and-post surveys and evaluation.
You will receive your certificate as a downloadable file.
Med Learning Group makes every effort to develop CME activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision making before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at [email protected].
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at http://medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]
Copyright © 2022 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.